Pfizer’s Phase II trial of meningococcal group B vaccine meets co-primary immunogenicity objectives
The Phase II trial met its co-primary immunogenicity objectives regarding co-administration of Trumenba with MCV4 and Tdap vaccines. The randomized, controlled, observer-blinded Phase II trial evaluated the safety,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.